Results 121 to 130 of about 46,519 (250)

Allopurinol administered prior to hepatic ischaemia in the rat prevents chemiluminescence following restoration of circulation [PDF]

, 1992
Peter J. Cohen
openalex   +1 more source

Severe cutaneous adverse drug reaction as a consequence of Allopurinol: The importance of HLA B58:01 testing [PDF]

, 2020
Keshav Poddar, Leslie Cler
openalex   +1 more source

Risk Factors for Cardiovascular and Metabolic Disease: Integrating Traditional and Novel Paradigms

iNew Medicine, Volume 1, Issue 1, December 2025.
ABSTRACT Cardiovascular and metabolic diseases (CVMD), encompassing atherosclerotic cardiovascular disease (ASCVD), heart failure, obesity, type 2 diabetes mellitus (T2DM), and metabolic dysfunction‐associated steatotic liver disease (MASLD), remain the leading global cause of morbidity and mortality.
Zhihua Wang, Shuo Chen, Suowen Xu, Jianping Weng   +3 more
wiley   +1 more source

Association between allopurinol and hepatocellular carcinoma: analysis of genetic risk and patient survival

Discover Oncology
Background Despite the widespread clinical use of allopurinol for managing hepatocellular carcinoma (HCC) and gout, its potential hepatotoxicity and its effect on the risk of HCC remain unclear.
Yu-fu Li, Hui-wei Wang, Huan-yan Peng, Zhen-ying Zhang, Zhi-jia Yao, Yuan Meng, Dong-ye Yang   +6 more
doaj   +1 more source

Effects of allopurinol and febuxostat on uric acid transport and transporter expression in human umbilical vein endothelial cells.

PLoS ONE
Uric acid induces radical oxygen species formation, endothelial inflammation, and endothelial dysfunction which contributes to the progression of atherosclerosis.
Karel H van der Pol, Jan Koenderink, Jeroen J M W van den Heuvel, Petra van den Broek, Janny Peters, Imke D W van Bunningen, Jeanne Pertijs, Frans G M Russel, Jim Koldenhof, Wim J Morshuis, Joris van Drongelen, Tom J J Schirris, Andries van der Meer, Gerard A Rongen   +13 more
doaj   +1 more source

Renoprotective impact of allopurinol in elderly patients with hypertension [PDF]

, 2017
Peyman Mottaghi
openalex   +1 more source

Evaluation of a 12-week allopurinol-lowering therapy in combination with the non-steroidal anti-inflammatory drug meloxicam in patients with gout [PDF]

, 2020
Margarita Aleksandrovna Gromova, В В Цурко, O. A. Кislyak, Н. В. Малышева   +3 more
openalex   +1 more source

Firsekibart as a Prophylactic Treatment for Acute Gout Flare in Participants Initiating Urate‐Lowering Therapy: A Phase 2, Randomized, Open‐Label, Multicenter, Active‐Controlled Trial

ACR Open Rheumatology, Volume 7, Issue 11, November 2025.
Objective To evaluate the efficacy and safety of firsekibart versus colchicine for prophylaxis against acute gout flares in participants initiating urate‐lowering therapy (ULT). Methods In this randomized, multicenter, open‐label, active‐controlled, phase 2 trial, participants were randomized (1:1:1) to receive a single subcutaneous injection of ...
Yiyun Yu, Yu Xue, Jiankang Hu, Ning Zhang, Rongbin Li, Hongtao Guo, Long Qian, Wei Gou, Jing Yang, Li Mao, Jing Yu, Shengyun Liu, Qian Xu, Tianhong Luo, Hejian Zou   +14 more
wiley   +1 more source

Topiroxostat versus allopurinol in patients with chronic heart failure complicated by hyperuricemia: A prospective, randomized, open-label, blinded-end-point clinical trial

PLoS ONE, 2022
Background The benefits of xanthine oxidase inhibitors to chronic heart failure (CHF) patients is controversial. We investigated the beneficial effects of a novel xanthine oxidoreductase inhibitor, topiroxostat, in patients with CHF and hyperuricemia (HU)
Masashi Sakuma, Shigeru Toyoda, Takuo Arikawa, Yota Koyabu, Toru Kato, Taichi Adachi, Hideaki Suwa, Jun-ichi Narita, Koetsu Anraku, Kimihiko Ishimura, Fumitake Yamauchi, Yasunori Sato, Teruo Inoue   +12 more
doaj  

Trends in drug–drug interaction prevalence and longitudinal associations with health outcomes in the older community‐dwelling population: Findings from The Irish LongituDinal study on Ageing

British Journal of Clinical Pharmacology, Volume 91, Issue 11, Page 3244-3256, November 2025.
Aims We estimate trends in severe drug–drug interaction (DDI) prevalence and examine longitudinal associations between DDI exposure and health outcomes (emergency department [ED] visits, quality‐of‐life [QoL] and functional decline) over approximately 10‐years in the older community‐dwelling population in Ireland.
John E. Hughes, Caitriona Cahir, Kathleen E. Bennett   +2 more
wiley   +1 more source